These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 19246730)

  • 1. Trial treatment length optimization with an emphasis on disease progression studies.
    Hennig S; Nyberg J; Hooker AC; Karlsson MO
    J Clin Pharmacol; 2009 Mar; 49(3):323-35. PubMed ID: 19246730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using disease progression models as a tool to detect drug effect.
    Mould DR; Denman NG; Duffull S
    Clin Pharmacol Ther; 2007 Jul; 82(1):81-6. PubMed ID: 17507925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Introduction of quantitative methods in pharmacology and clinical pharmacology: a historical overview.
    Atkinson AJ; Lalonde RL
    Clin Pharmacol Ther; 2007 Jul; 82(1):3-6. PubMed ID: 17571065
    [No Abstract]   [Full Text] [Related]  

  • 4. Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis.
    Ploeger BA; Holford NH
    Pharm Stat; 2009; 8(3):225-38. PubMed ID: 19025967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacometrics at FDA: evolution and impact on decisions.
    Powell JR; Gobburu JV
    Clin Pharmacol Ther; 2007 Jul; 82(1):97-102. PubMed ID: 17538553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease modifying trials in Alzheimer disease: methodological and statistical issues.
    Andrieu S; Rascol O; Lang T; Grandjean H; Vellas B
    J Nutr Health Aging; 2006; 10(2):116-7. PubMed ID: 16554944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sample size determination in clinical trials with an emphasis on exponentially distributed responses.
    Gross AJ; Hunt HH; Cantor AB; Clark BC
    Biometrics; 1987 Dec; 43(4):875-83. PubMed ID: 3427172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trial simulation: a review.
    Holford N; Ma SC; Ploeger BA
    Clin Pharmacol Ther; 2010 Aug; 88(2):166-82. PubMed ID: 20613720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Getting the dose right": facts, a blueprint, and encouragements.
    Peck CC; Cross JT
    Clin Pharmacol Ther; 2007 Jul; 82(1):12-4. PubMed ID: 17571068
    [No Abstract]   [Full Text] [Related]  

  • 10. Optimal adaptive design in clinical drug development: a simulation example.
    Maloney A; Karlsson MO; Simonsson US
    J Clin Pharmacol; 2007 Oct; 47(10):1231-43. PubMed ID: 17906158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling.
    Ince I; de Wildt SN; Tibboel D; Danhof M; Knibbe CA
    Drug Discov Today; 2009 Mar; 14(5-6):316-20. PubMed ID: 19059496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonparametric confidence intervals for Tmax in sequence-stratified crossover studies.
    Willavize SA; Morgenthien EA
    Pharm Stat; 2008; 7(1):9-19. PubMed ID: 17256803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Basic concepts in pharmacology: important terms in pharmacodynamics and pharmacokinetics].
    Singer E
    Onkologie; 2008; 31 Suppl 2():21-4. PubMed ID: 18487864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal design of pharmacokinetic studies.
    Aarons L; Ogungbenro K
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):250-5. PubMed ID: 20102362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonparametric estimation of duration of accrual and total study length for clinical trials.
    Morgan TM
    Biometrics; 1987 Dec; 43(4):903-12. PubMed ID: 3427175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal Bayesian design for patient selection in a clinical study.
    Buzoianu M; Kadane JB
    Biometrics; 2009 Sep; 65(3):953-61. PubMed ID: 19021600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimum blood sampling time windows for parameter estimation in population pharmacokinetic experiments.
    Graham G; Aarons L
    Stat Med; 2006 Dec; 25(23):4004-19. PubMed ID: 16463254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal design of clinical trials with computer simulation based on results of earlier trials, illustrated with a lipodystrophy trial in HIV patients.
    Abbas I; Rovira J; Casanovas J; Greenfield T
    J Biomed Inform; 2008 Dec; 41(6):1053-61. PubMed ID: 18534916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapy in shock syndromes: the neglected field of pharmacokinetics and pharmacodynamics.
    Neugebauer E; Dietrich A; Lechleuthner A; Bouillon B; Eypasch E
    Circ Shock; 1992 Apr; 36(4):312-20. PubMed ID: 1623575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
    Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
    Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.